Internal Medicine, Endocrinology, Diabetes, & Metabolism · New York, NY
NPI
1316250582
Since 2010
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
309 W 23rd St Fl 2
New York, NY, 10011
Phone (212) 352-2600
Groups this clinician bills Medicare through
Medicare paid, 2024
$152K
5,365 services
Medicare patients, 2024
311
Average age 73
Drug cost, 2024
$2.4M
4,178 prescriptions
Company payments, 2025
$340
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Cesar Abuchaibe was code J0897 (injection, denosumab, 1 mg), 4,620 times for 42 patients. In total Cesar Abuchaibe billed 5,365 services in 11 codes, and Medicare paid $152K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-03-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 4,620 | 42 | $20.59 | $95K |
| 99214 Office E&M - Established | Office | 520 | 275 | $94.29 | $49K |
| 36415 Venipuncture Blood Collection | Office | 171 | 110 | $8.65 | $1,479 |
| 99204 Office E&M - New | Office | 47 | 47 | $131.72 | $6,191 |
By year: 2022 $110K for 3,137 services; 2023 $151K for 5,533 services; 2024 $152K for 5,365 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 171 | 110 | $8.65 | $1,479 |
Medicare prescription drug claims, 2024
In 2024, the drug Cesar Abuchaibe prescribed most often to Medicare patients was Levothyroxine Sodium, with 401 prescriptions and refills. In total Cesar Abuchaibe wrote 4,178 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 401 | 1,037 | 109 | $5,466 |
| Mounjaro Tirzepatide | 329 | 424 | 53 | $447K |
| Ozempic Semaglutide | 279 | 549 | 77 | $513K |
| Glipizide Er Glipizide | 206 | 563 | 69 | $4,638 |
| Synjardy Empagliflozin/Metformin Hcl | 183 | 387 | 54 | $219K |
| Metformin Hcl Er Metformin Hcl | 171 | 441 | 56 | $2,889 |
| Atorvastatin Calcium Generic | 151 | 405 | 53 | $1,496 |
| Jardiance Empagliflozin | 144 | 337 | 34 | $193K |
| Januvia Sitagliptin Phosphate | 116 | 256 | 37 | $138K |
| Pioglitazone Hcl Generic | 108 | 291 | 33 | $1,426 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 100 | 201 | 27 | $13K |
| Xigduo Xr Dapaglifloz Propaned/Metformin | 95 | 247 | 28 | $132K |
| Synjardy Xr Empagliflozin/Metformin Hcl | 87 | 228 | 29 | $116K |
| Alendronate Sodium Generic | 85 | 231 | 28 | $665 |
| Janumet Sitagliptin Phos/Metformin Hcl | 67 | 115 | 13 | $61K |
Brand drugs: 2,071 claims; generic drugs: 1,926 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Cesar Abuchaibe $340 ($340 in general payments such as food, travel and fees) from 1 company. The largest payer was Novo Nordisk Inc with $340.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 9 | $340 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.